Oral Cancer – Pipeline Review, H1 2013

Global Markets Direct
February 28, 2013
40 Pages - SKU: GMD4986573
Introduction
Global Markets Direct Report Coverage
Oral Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Oral Cancer
Oral Cancer Therapeutics under Development by Companies
Oral Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Oral Cancer Therapeutics – Products under Development by Companies
Oral Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Oral Cancer Therapeutics Development
NexMed, Inc.
Oral Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
HPPH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bevacizumab + [cisplatin] + [docetaxel] + [fluorouracil] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Survivin-Derived Peptide Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Cisplatin + 5-Fluorouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Taxotere + Cisplatin + 5-FU - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vesnarinone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
curcumin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
celecoxib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interleukin-15 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oral Cancer Therapeutics – Drug Profile Updates
Oral Cancer Therapeutics – Discontinued Products
Oral Cancer Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Oral Cancer, H1 2013
Products under Development for Oral Cancer – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
NexMed, Inc., H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Oral Cancer Therapeutics – Drug Profile Updates
Oral Cancer Therapeutics – Discontinued Products
Oral Cancer Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Oral Cancer, H1 2013
Products under Development for Oral Cancer – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Late Stage Products, H1 2013
Mid Clinical Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013
 

SELECT A LICENSE

    Online Download  USD 2,000  
    Site License  USD 4,000  
    Global Site License  USD 6,000  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!